These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 4795621)

  • 1. The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.
    Brade V; Lee GD; Nicholson A; Shin HS; Mayer MM
    J Immunol; 1973 Nov; 111(5):1389-400. PubMed ID: 4795621
    [No Abstract]   [Full Text] [Related]  

  • 2. Formation of the C3-cleaving properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes.
    Brade V; Nicholson A; Bitter-Suermann D; Hadding U
    J Immunol; 1974 Dec; 113(6):1735-43. PubMed ID: 4279261
    [No Abstract]   [Full Text] [Related]  

  • 3. Kinetic studies of the formation of the properdin system enzymes on zymosan: evidence that nascent C3b controls the rate of assembly.
    Nicholson A; Brade V; Lee GD; Shin HS; Mayer MM
    J Immunol; 1974 Mar; 112(3):1115-23. PubMed ID: 4811964
    [No Abstract]   [Full Text] [Related]  

  • 4. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
    Vogt W; Schmidt G; Lynen R; Dieminger L
    J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
    Brade V; Bentley C; Bitter-Suermann D; Hadding U
    Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The reaction of zymosan with the properdin system: isolation of purified factor D from guinea pig serum and study of its reaction characteristics.
    Brade V; Nicholson A; Lee GD; Mayer MM
    J Immunol; 1974 May; 112(5):1845-54. PubMed ID: 4818461
    [No Abstract]   [Full Text] [Related]  

  • 7. Activation of factor B and C3 in guinea pig serum by zymosan or by activated properdin depends on the presence of factor D.
    Brade V; Bentley C; Kossorotow A; Bitter-Suermann D
    Monogr Allergy; 1977; 12():83-5. PubMed ID: 917024
    [No Abstract]   [Full Text] [Related]  

  • 8. The utilization of properdin in the alternate pathway of complement activation: isolation of properdin convertase.
    Stitzel AE; Spitzer RE
    J Immunol; 1974 Jan; 112(1):56-62. PubMed ID: 4130153
    [No Abstract]   [Full Text] [Related]  

  • 9. Anaphylatoxin formation by contact activation of plasma. II. Implication of properdin and an unknown plasma factor in activation by zymosan.
    Brade V; Vogt W
    Eur J Immunol; 1971 Aug; 1(4):295-300. PubMed ID: 4945686
    [No Abstract]   [Full Text] [Related]  

  • 10. Bypass-activation of the complement system starting with C3. I. Generation and function of an enzyme from a factor of guinea-pig serum and cobra venom.
    Bitter-Suermann D; Dierich M; König W; Hadding U
    Immunology; 1972 Sep; 23(3):267-81. PubMed ID: 4214761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.
    Ziegler JB; Alper CA; Rosen RS; Lachmann PJ; Sherington L
    J Clin Invest; 1975 Mar; 55(3):668-72. PubMed ID: 1117072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation and characterization of Guinea pig properidin.
    Nicholson A; Austen KF
    J Immunol; 1977 Jan; 118(1):103-8. PubMed ID: 830742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaphylatoxin formation by contact activation of plasma. 3. Fixation of two different anaphylatoxin-forming complexes on zymosan.
    Brade V; Schmidt G; Vogt W
    Eur J Immunol; 1972 Apr; 2(2):180-6. PubMed ID: 4644242
    [No Abstract]   [Full Text] [Related]  

  • 14. Blocking of the hemolytic expression of the classical complement sequence by products of complement activation via the alternate pathway. Materials responsible for the blocking phenomenon and their proposed mechanism of action.
    Koethe SM; Austen KF; Gigli I
    J Immunol; 1973 Feb; 110(2):390-400. PubMed ID: 4684033
    [No Abstract]   [Full Text] [Related]  

  • 15. Humoral immunostimulation. IV. Role of complement.
    Shearer WT; Atkinson JP; Frank MM; Parker CW
    J Exp Med; 1975 Apr; 141(4):736-52. PubMed ID: 1168690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activation in semisolid media: insolubilization of alternative pathway convertases in agar gels with C3 nephritic factor-containing sera.
    Arnaout MA; Davis AE; Rosen RS; Alper CA
    J Immunol; 1977 Oct; 119(4):1316-20. PubMed ID: 894039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of anticomplementary substances on properdin in normal and C2-deficient sera.
    McLean RH; Townsend K; Michael AF
    Clin Exp Immunol; 1975 Mar; 19(3):435-44. PubMed ID: 1204244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C3 and C5-cleaving properdin enzymes formed on zymosan incubated with human serum: the decay and the regeneration of the enzymes.
    Fujita T; Takiuchi M; Matsumoto M; Nagaki K; Inai S
    Int Arch Allergy Appl Immunol; 1977; 53(4):303-9. PubMed ID: 67089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of the classical and alternate complement pathway with endotoxin lipopolysaccharide. Effect on platelets and blood coagulation.
    Kane MA; May JE; Frank MM
    J Clin Invest; 1973 Feb; 52(2):370-6. PubMed ID: 4683877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.